M&A Deal Summary

AbbVie Acquires Nimble Therapeutics

On December 13, 2024, AbbVie acquired life science company Nimble Therapeutics from Telegraph Hill Partners

Acquisition Highlights
  • This is AbbVie’s 13th transaction in the Life Science sector.
  • This is AbbVie’s 11th transaction in the United States.
  • This is AbbVie’s 1st transaction in Wisconsin.

M&A Deal Summary
Date 2024-12-13
Target Nimble Therapeutics
Sector Life Science
Buyer(s) AbbVie
Sellers(s) Telegraph Hill Partners
Deal Type Add-on Acquisition

Target

Nimble Therapeutics

Madison, Wisconsin, United States
Nimble Therapeutics is a provider of massively parallel chemical synthesis to drug discovery. Nimble’s proprietary technology enables the synthesis and screening of millions of peptides, including scaffolded natural and modified macrocyclic peptidomimetics. Nimble Therapeutics was founded in 2019 and is based in Madison, Wisconsin.

Search 201,539 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AbbVie

North Chicago, Illinois, United States
Category Company
Founded 2012
Sector Life Science
Employees50,000
Revenue 54.3B USD (2023)
DESCRIPTION
Entrance to Abbvie's office in Lake Forest, Illinois.
Entrance to Abbvie's office in Lake Forest, Illinois.

AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.

DEAL STATS #
Overall 13 of 13
Sector (Life Science) 13 of 13
Type (Add-on Acquisition) 12 of 12
State (Wisconsin) 1 of 1
Country (United States) 11 of 11
Year (2024) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-10-28 Aliada Therapeutics

Boston, Massachusetts, United States

Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in CNS drug development. Aliada Therapeutics is based in Boston, Massachusetts.

Buy $1.4B

Seller(S) 1

SELLER

Telegraph Hill Partners

San Francisco, California, United States

Investor Investor Investor Investor Investor

Category Venture Capital Firm
Founded 2001
Size Middle-Market
Type Sector Focused
DESCRIPTION

Telegraph Hill Partners is a specialist private equity firm focused on investing in later-stage life science, medical device, and healthcare companies. Prospective companies should be at or near profitability and demonstrate success. Other areas of interest within the healthcare sector include life science technologies, chemistry/reagent suppliers, and information management. Telegraph Hill Partners was formed in 2001 and is based in San Francisco, California.

DEAL STATS #
Overall 29 of 29
Sector (Life Science) 13 of 13
Type (Add-on Acquisition) 24 of 24
State (Wisconsin) 2 of 2
Country (United States) 28 of 28
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-09 Verogen

San Diego, California, United States

Verogen is a developer, manufacturer, and sells forensic genomics products and services, including for next-generation sequencing. Verogen was formed in 2017 and is based in San Diego, California.

Sell $150M
Mergr

Product

Company

Legal